Vasculitis Market Research Report By Disease Type (Giant Cell Arteritis, Takayasu Arteritis, ANCA-Associated Vasculitis, Behet's Disease, Kawasaki Disease), By Treatment Type (Immunosuppressive Therapy, Biologic Therapy, Glucocorticoids, Anticoagulants, Surgery), By Patient Demographics (Age, Gender, Ethnicity, Comorbidities), By Severity (Mild, Moderate, Severe), By Treatment Setting (Hospital, Clinic, Home) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Forecast to 2032

Vasculitis Market Overview

As per MRFR analysis, the Vasculitis Market Size was estimated at 2.52 (USD Billion) in 2022. The Vasculitis Market Industry is expected to grow from 2.67(USD Billion) in 2023 to 4.6 (USD Billion) by 2032. The Vasculitis Market CAGR (growth rate) is expected to be around 6.22% during the forecast period (2024 - 2032).

Key Vasculitis Market Trends Highlighted

The Vasculitis Market exhibits notable trends that shape its landscape. Key market drivers include the increasing prevalence of autoimmune diseases, advancements in diagnostic techniques, and growing awareness about vasculitis. Technological advancements, such as the development of targeted therapies and biomarkers for early detection, present opportunities for exploration. Trends in recent times include the emergence of personalized medicine, the integration of artificial intelligence into diagnostics, and the focus on minimally invasive treatment options. These trends reflect the evolving nature of the vasculitis market and pave the way for continued growth and innovation in the future.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Vasculitis Market Drivers

Growing Prevalence of Vasculitis

A Vasculitis Market industry report gave some valuable information about vasculitis. The disease is relatively rare and it is characterized by inflammation of the blood vessels. The main reasons for this condition are unknown, but scientists believe that the disease may be caused by a combination of genetic and environmental factors. Increasing prevalence of vasculitis is driving growth in the Vasculitis Market Industry. It is estimated that there are over 1 million people worldwide living with this condition and as the number of people with vasculitis is increasing, the demand for treatment is also rising.

Rising Demand for Advanced Treatment Options

Vasculitis treatment has changed significantly with the introduction of new and more effective medications in the past years. As a result, the outcomes for the individuals affected by this disease become better and the possibilities of severe complications are significantly minimized. One of the key market drivers in the case of the development of the Vasculitis Market Industry is the expansion of the demand for advanced ways of treatment, stimulated by the increasing number of people who are diagnosed with vasculitis.

Increasing Awareness of Vasculitis

Awareness of vasculitis is increasing among both healthcare professionals and the general public. This increased awareness is leading to earlier diagnosis and treatment of the condition, which is improving outcomes for patients. The increasing awareness of vasculitis is a major driver of growth in the Vasculitis Market Industry. As more people become aware of the condition, the demand for diagnosis, treatment, and management services will continue to increase.

Vasculitis Market Segment Insights

Vasculitis Market Disease Type Insights

The Vasculitis Market segmentation by Disease Type provides valuable insights into the diverse range of vasculitis conditions. Giant Cell Arteritis, with an estimated 2023 market size of USD 0.69 billion, is characterized by inflammation of large arteries, primarily affecting the head and neck. Takayasu Arteritis, with a projected market value of USD 0.45 billion in 2023, involves inflammation of the aorta and its major branches. Anca-associated vasculitis, estimated to reach USD 0.83 billion in 2024, encompasses conditions such as Granulomatosis with Polyangiitis and Microscopic Polyangiitis, affecting small and medium-sized blood vessels.Behet's Disease, with a market size of around USD 0.32 billion in 2023, is characterized by inflammation of blood vessels, along with symptoms such as oral ulcers and skin lesions. Kawasaki Disease, predominantly affecting children, has an estimated market value of USD 0.26 billion in 2023. It involves inflammation of medium-sized arteries, leading to fever, rash, and swelling of lymph nodes. The market segmentation by Disease Type enables targeted therapeutic approaches and supports the development of specialized treatments for each specific vasculitis condition.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Vasculitis Market Treatment Type Insights

The market is segmented across the treatment types: Immunosuppressive Therapy, Biologic Therapy, Glucocorticoids, Anticoagulants and Surgery. Immunosuppressive Therapy had the largest market size in the vasculitis market in 2023. Biologic Therapy will be the fastest-growing segment during the forecast period in the vasculitis market. This is mainly because they can be used to target the specific cells responsible for causing vasculitis. The increasing technological advancements in the field of biotechnology will also drive the demand for this segment.Glucocorticoids are used as initial treatment for vasculitis patients as they are potent anti-inflammatory and immunosuppressive agents.

Anticoagulants are prescribed for patients with vasculitis to either prevent blood clots from developing or to treat existing blood clots. Surgeries are only performed in cases where there are major complications or in severe cases of vasculitis. It is also based on the specific type of vasculitis that the patient is affected with. The Vasculitis Market is expected to reach a total market size of USD 2.89 billion by the end of 2023, with a CAGR of 6.5% throughout the forecast period.The rise in the number of cases of vasculitis, the increasing demand for more specialized treatments and the new launches of newer therapies are the key factors for the growth of the market. The residual markets of the Asia Pacific are also expected to have a significant impact on the demand for market growth.

Vasculitis Market Patient Demographics Insights

Vasculitis Market segmentation by Patient Demographics provides valuable insights into the characteristics of individuals affected by vasculitis. The market data indicates that age plays a significant role, with the elderly population being more susceptible to the condition. Statistics reveal that individuals over the age of 65 account for a substantial proportion of vasculitis cases. Gender distribution also influences the market, with a slightly higher prevalence among females compared to males. Ethnicity and comorbidities are other crucial factors to consider.The Vasculitis Market industry observes variations in vasculitis prevalence across different ethnic groups, with certain populations exhibiting a higher risk. Additionally, the presence of comorbidities such as hypertension, diabetes, and autoimmune disorders can impact the presentation and severity of vasculitis. Understanding these patient demographics is essential for developing targeted healthcare strategies, optimizing treatment approaches, and addressing the specific needs of individuals affected by vasculitis.

Vasculitis Market Severity Insights

The severity of vasculitis can vary widely, ranging from mild to moderate to severe. The Vasculitis Market segmentation by severity provides valuable insights into the prevalence and impact of each category. According to market data, mild vasculitis accounts for the largest share of the market, with an estimated revenue of USD 1.2 billion in 2023. This is attributed to its relatively common occurrence and less severe symptoms. Moderate vasculitis holds the second-largest share, with an estimated revenue of USD 0.9 billion in 2023. Severe vasculitis, while less common, represents a significant unmet medical need and contributes to a revenue of USD 0.5 billion in 2023.The market growth for each segment is influenced by factors such as disease prevalence, treatment advancements, and reimbursement policies. Understanding the severity segmentation of the Vasculitis Market enables stakeholders to develop targeted therapies, optimize patient management, and address the varying needs of patients with vasculitis.

Vasculitis Market Treatment Setting Insights

The Vasculitis Market segmentation by Treatment Setting includes Hospitals, Clinics, and Homes. Among these, Hospital segment held the largest share in the Vasculitis Market in 2023 and is expected to continue its dominance during the forecast period. This is attributed to factors such as the availability of advanced healthcare facilities, experienced medical professionals, and comprehensive patient care in hospital settings. However, the Clinic segment is expected to witness a higher CAGR during the forecast period due to growing adoption of outpatient treatments and increasing investment in ambulatory surgery centers.The Home segment is also expected to grow steadily, driven by factors such as technological advancements in home healthcare devices and increasing preference for home-based care.

Vasculitis Market Regional Insights

The market growth is attributed to the increasing prevalence of vasculitis, rising awareness of the disease, and the development of new and more effective treatments. Regionally, North America held the largest market share in 2023 and is expected to continue to dominate the market over the forecast period. This is due to the high prevalence of vasculitis in the region, as well as the presence of a large number of key players in the market. Europe is the second largest market for vasculitis, followed by APAC. The APAC region is expected to witness the highest growth rate over the forecast period due to the increasing awareness of vasculitis and the rising disposable income of the population.South America and MEA are expected to account for a smaller share of the Vasculitis Market. Some of the key players in the Vasculitis Market include F. Hoffmann-La Roche Ltd., Novartis AG, Bristol-Myers Squibb Company, Merck Co., Inc., and Pfizer Inc. These companies are involved in the development, manufacturing, and marketing of vasculitis drugs and therapies.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Vasculitis Market Key Players And Competitive Insights

Key industry players in the Vasculitis Market are actively developing and launching novel medications to meet patients’ needs. For example, in February 2023, F. Hoffmann-La Roche Ltd. received approval from the U.S. Food and Drug Administration for its subcutaneous tocilizumab product, Actemra Injection for untreated COVID-19 in people 2 years of age and older requiring ventilators and supportive measures in a health facility. The Leading Vasculitis Market players are also seeking to enhance their competitive position in emerging markets through collaborations and acquisitions.

In March, Allergan, a dominant player in the botulinum toxin sector, was acquired by AbbVie to enhance company strength in the aesthetic business with Allergan’s existing Vasculitis treatment products. The Vasculitis Market continues to experience intense rivalry and high degrees of innovation. Major players are also investing heavily in research and development to produce excellent or modified products.

UCB, with its prevalence in the pharmaceutical sector, is a key industry player. Cimzia and Kineret are UCB products that are both marketed and have a strong portfolio in the molecular structure and activity field. In addition, UCB has a substantial research program with numerous competitive candidates. It has the ability to remain a significant player in the Vasculitis Market.

GlaxoSmithKline is another major Vasculitis Market player. The company markets Arzerra and Benlysta in the field of molecular structure and activity. Moreover, GlaxoSmithKline’s research program includes a number of challenging candidates. The company has the capacity to remain a significant player in the Vasculitis Market.

Key Companies in the Vasculitis Market Include

• GSK


• Janssen


• UCB


• Pfizer


• Eli Lilly


• BristolMyers Squibb


• Celgene


• Amgen


• Takeda


• Bayer


• AbbVie


• AstraZeneca


• Novartis


• Roche


• Sanofi

Vasculitis Market Industry Developments

The Vasculitis Market is anticipated to reach USD 4.6 billion by 2032, expanding at a 6.22% CAGR from 2024 to 2032. Rising prevalence of vasculitis, increasing research and development activities, and growing adoption of biologics drive market expansion.

 Recent developments include the FDA approval of intravenous (IV) tocilizumab for treating giant cell arteritis (GCA) and polyarteritis nodosa (PAN). Moreover, the introduction of novel therapies, such as interleukin-6 (IL-6) inhibitors and JAK inhibitors, offers promising treatment options. Market growth may face challenges due to the high cost of biologics and the potential for adverse effects associated with long-term use.

Vasculitis Market Segmentation Insights

Vasculitis Market Disease Type Outlook

• 
  
  
  
  • Giant Cell Arteritis
  
  
  • Takayasu Arteritis
  
  
  • ANCA-Associated Vasculitis
  
  
  • Behet's Disease
  
  
  • Kawasaki Disease
  
  
  
  

Vasculitis Market Treatment Type Outlook

• 
  
  
  
  • Immunosuppressive Therapy
  
  
  • Biologic Therapy
  
  
  • Glucocorticoids
  
  
  • Anticoagulants
  
  
  • Surgery
  
  
  
  

Vasculitis Market Patient Demographics Outlook

• 
  
  
  
  • Age
  
  
  • Gender
  
  
  • Ethnicity
  
  
  • Comorbidities
  
  
  
  

Vasculitis Market Severity Outlook

• 
  
  
  
  • Mild
  
  
  • Moderate
  
  
  • Severe
  
  
  
  

Vasculitis Market Treatment Setting Outlook

• 
  
  
  
  • Hospital
  
  
  • Clinic
  
  
  • Home
  
  
  
  

Vasculitis Market Regional Outlook

• 
  
  
  
  • North America
  
  
  • Europe
  
  
  • South America
  
  
  • Asia Pacific
  
  
  • Middle East and Africa